MiNK Therapeutics' new data highlights its shelf-stable iNKT cell therapy targeting two key mechanisms of tumor resistance presented at the Society for Cancer Immunotherapy (SITC 2026).
MiNK Therapeutics' new data highlights its shelf-stable iNKT cell therapy targeting two key mechanisms of tumor resistance presented at the Society for Cancer Immunotherapy (SITC 2026).
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in